{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:53:11Z","timestamp":1761897191003,"version":"3.37.3"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Research Scholar Grant"},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["K24CA181510"],"award-info":[{"award-number":["K24CA181510"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Center for Advancing Translational Sciences, National Institutes","award":["KL2TR001438","128608-RSGI-15-211-01-CPHPS"],"award-info":[{"award-number":["KL2TR001438","128608-RSGI-15-211-01-CPHPS"]}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In this study, we sought to estimate the association between oral oncology parity law adoption and anticancer medication use for patients with chronic myeloid leukemia or multiple myeloma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was an observational study of administrative claims from 2008 to 2017. Among individuals initiating tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia or immunomodulatory drugs for multiple myeloma, we compared out-of-pocket spending, adherence, and discontinuation before and after parity among individuals in fully insured plans (subject to parity) vs self-funded plans (exempt from parity) using propensity-score weighted difference-in-differences regression models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among patients initiating TKIs (N\u2009=\u20092082) or immunomodulatory drugs (N\u2009=\u20093326) there were no statistically significant differences in adherence or discontinuation associated with parity. The proportion of patients with initial out-of-pocket payments of $0 increased in fully insured plans after parity from 5.7% to 46.1% for TKIs and from 10.9% to 48.8% for immunomodulatory drugs. Relative to changes in self-funded plans, those in fully insured plans were 4.27 (95% CI = 2.20 to 8.27) times as likely to pay nothing for TKIs and 1.96 (95% CI = 1.40 to 2.73) times as likely to pay nothing for immunomodulatory drugs after parity. Similarly, the proportion paying more than $100 decreased from 30.3% to 24.7% for TKIs and 30.6% to 27.5% for immunomodulatory drugs in fully insured plans after parity. Relative to changes in self-funded plans, those in fully insured plans were 0.74 (95% CI = 0.54 to 1.01) times as likely to pay more than $100 for TKIs and 0.85 (95% CI = 0.68 to 1.06) times as likely to pay more than $100 for immunomodulatory drugs after parity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Among patients initiating TKIs or immunomodulatory drugs, parity was not associated with better adherence or less discontinuation of therapy but yielded decreased patient out-of-pocket payments for some patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jnci\/djz243","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T20:09:24Z","timestamp":1577218164000},"page":"1055-1062","source":"Crossref","is-referenced-by-count":12,"title":["Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients With Blood Cancers"],"prefix":"10.1093","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3907-9196","authenticated-orcid":false,"given":"Stacie B","family":"Dusetzina","sequence":"first","affiliation":[{"name":"Department of Health Policy, Vanderbilt University School of Medicine, Nashville, TN, USA"},{"name":"Vanderbilt-Ingram Comprehensive Cancer Center, Nashville, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiden A","family":"Huskamp","sequence":"additional","affiliation":[{"name":"Department of Health Care Policy, Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3467-2502","authenticated-orcid":false,"given":"Shelley A","family":"Jazowski","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA"},{"name":"Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2906-3913","authenticated-orcid":false,"given":"Aaron N","family":"Winn","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, School of Pharmacy, Milwaukee, WI, USA"},{"name":"Center for Advancement of Population Science, Medical College of Wisconsin, Milwaukee, WI, USA"},{"name":"Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A","family":"Wood","sequence":"additional","affiliation":[{"name":"School of Medicine, Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA"},{"name":"UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6472-6658","authenticated-orcid":false,"given":"Adam","family":"Olszewski","sequence":"additional","affiliation":[{"name":"Brown University, Providence, RI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan","family":"Basch","sequence":"additional","affiliation":[{"name":"School of Medicine, Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA"},{"name":"UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy L","family":"Keating","sequence":"additional","affiliation":[{"name":"Department of Health Care Policy, Harvard Medical School, Boston, MA, USA"},{"name":"Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,12,27]]},"reference":[{"issue":"5S","key":"2020101503545161900_djz243-B1","doi-asserted-by":"crossref","first-page":"624","DOI":"10.6004\/jnccn.2018.0040","article-title":"Management of multiple myeloma","volume":"16","author":"Kumar","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"2020101503545161900_djz243-B2","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"Radich","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"2020101503545161900_djz243-B3","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamainternmed.2014.4878","article-title":"Chemotherapy parity laws: a remedy for high drug costs?","volume":"174","author":"Wang","year":"2014","journal-title":"JAMA Intern Med"},{"year":"2012","key":"2020101503545161900_djz243-B4"},{"issue":"3S","key":"2020101503545161900_djz243-B5","doi-asserted-by":"crossref","first-page":"9s","DOI":"10.1200\/JOP.2011.000516","article-title":"Patient out-of-pocket payments for oral oncolytics: results from a 2009 US claims data analysis","volume":"8","author":"Raborn","year":"2012","journal-title":"J Oncol Pract"},{"issue":"3S","key":"2020101503545161900_djz243-B6","doi-asserted-by":"crossref","first-page":"46s","DOI":"10.1200\/JOP.2011.000316","article-title":"Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions","volume":"7","author":"Streeter","year":"2011","journal-title":"J Oncol Pract"},{"issue":"5","key":"2020101503545161900_djz243-B7","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1200\/JCO.2017.74.5091","article-title":"Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents","volume":"36","author":"Doshi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"36","key":"2020101503545161900_djz243-B8","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2016.67.4184","article-title":"Factors associated with tyrosine kinase inhibitor initiation and adherence among Medicare beneficiaries with chronic myeloid leukemia","volume":"34","author":"Winn","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020101503545161900_djz243-B9","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","article-title":"Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia","volume":"32","author":"Dusetzina","year":"2014","journal-title":"J Clin Oncol"},{"issue":"18","key":"2020101503545161900_djz243-B10","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1200\/JCO.2010.33.3179","article-title":"Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer","volume":"29","author":"Neugut","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020101503545161900_djz243-B11","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.clinthera.2011.04.021","article-title":"Retrospective evaluation of the impact of copayment increases for specialty medications on adherence and persistence in an integrated health maintenance organization system","volume":"33","author":"Kim","year":"2011","journal-title":"Clin Ther"},{"issue":"6","key":"2020101503545161900_djz243-B12","doi-asserted-by":"crossref","first-page":"e173598","DOI":"10.1001\/jamaoncol.2017.3598","article-title":"Out-of-pocket and health care spending changes for patients using orally administered anticancer therapy after adoption of state parity laws","volume":"4","author":"Dusetzina","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7\u20138","key":"2020101503545161900_djz243-B13","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1345\/aph.1H018","article-title":"Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures","volume":"40","author":"Hess","year":"2006","journal-title":"Ann Pharmacother"},{"issue":"22","key":"2020101503545161900_djz243-B14","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1001\/jama.2014.16153","article-title":"Methods for evaluating changes in health care policy: the difference-in-differences approach","volume":"312","author":"Dimick","year":"2014","journal-title":"JAMA"},{"year":"2007","author":"Wooldridge","key":"2020101503545161900_djz243-B15"},{"issue":"7","key":"2020101503545161900_djz243-B16","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified Poisson regression approach to prospective studies with binary data","volume":"159","author":"Zou","year":"2004","journal-title":"Am J Epidemiol"},{"key":"2020101503545161900_djz243-B17","first-page":"55","article-title":"Thinking beyond the mean: a practical guide for using quantile regression methods for health services research","volume":"25","author":"Le Cook","year":"2013","journal-title":"Shanghai Arch Psychiatry"},{"issue":"20","key":"2020101503545161900_djz243-B18","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1001\/jama.2019.4492","article-title":"Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in Medicare Part D, 2010 to 2019","volume":"321","author":"Dusetzina","year":"2019","journal-title":"JAMA"},{"key":"2020101503545161900_djz243-B19","first-page":"374","article-title":"The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer","author":"Chin","year":"2019","journal-title":"Cancer-Am Cancer Soc"},{"key":"2020101503545161900_djz243-B20","first-page":"88","article-title":"The parity paradigm: can legislation help reduce the cost burden of oral anticancer medications? Value Health","author":"Kircher","year":"2016"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djz243\/32926599\/djz243.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/112\/10\/1055\/33879493\/djz243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/112\/10\/1055\/33879493\/djz243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T07:55:12Z","timestamp":1602748512000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/112\/10\/1055\/5688751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,27]]},"references-count":20,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,12,27]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djz243","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"type":"print","value":"0027-8874"},{"type":"electronic","value":"1460-2105"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2019,12,27]]}}}